Get started
Long

AVEO missed earnings - kidney cancer treatment too thinly traded

By Pokethebear
Updated
Medical stock that's too thinly traded got mixed review on clinical trial results on Tivozanib, which showed efficacy, just not to level expected and testing new low for 2018 at 2.03 and below full fibonacci retracement of 2.10 as prior low. NASDAQ:AVEO
Note
snapshot
Currently at 618fibretracement
Note
Full 241% retracement and bounce to 161%. Sign of bouncing cat?
Beyond Technical AnalysisclinicalentrypointFibonaccifullretracementkidneyLOWNEWoncologypharmaceuticalspharmastocksSupply and Demand
Pokethebear

Disclaimer

The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.